New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Data ReadoutpositiveTREMFYA®Positive

AI Analysis

Summary

Johnson & Johnson announced new TREMFYA (guselkumab) study results demonstrating consistent perianal fistula remission across key Crohn's disease patient subgroups. This positive clinical data supports the therapeutic profile of guselkumab in this indication.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

Importance:6/10

Sentiment:

0.70

TREMFYAguselkumabCrohn's diseaseperianal fistulaclinical data

Related Companies

$JNJ

Read the original article

Published by yahoo_finance on October 12, 2026 8:05 PM

Read Original